Distributed biomanufacturing governance frameworks

Introduction

Distributed biomanufacturing governance frameworks refer to the legal, regulatory, and institutional arrangements governing the production of biological products across multiple geographically separated manufacturing facilities. Unlike traditional centralized manufacturing, distributed biomanufacturing involves smaller production units operating through interconnected networks of laboratories, biotechnology companies, research institutions, and healthcare organizations.

This manufacturing model uses biotechnology, synthetic biology, genetic engineering, automation, and digital monitoring systems to produce vaccines, pharmaceutical ingredients, biologics, enzymes, cultured food products, and other biological materials.

Distributed biomanufacturing offers several advantages, including improved supply-chain resilience, reduced transportation costs, faster access to essential medicines, and increased regional manufacturing capacity. However, it also creates regulatory challenges involving product quality, biosafety, environmental protection, intellectual property, data security, and accountability.

For example, when a biotechnology company operates manufacturing facilities in different Indian states, each facility must maintain appropriate regulatory approvals, quality-control systems, and safety standards. A failure at one location may affect the quality and safety of products distributed through the entire network.

Therefore, an effective governance framework is necessary to ensure that decentralized manufacturing remains scientifically reliable, legally compliant, and socially responsible.

Legal and regulatory framework in India

India regulates biomanufacturing through several interconnected legislative and regulatory frameworks.

1. Drugs and Cosmetics Act, 1940

The Drugs and Cosmetics Act, 1940 provides the principal statutory framework for regulating the manufacture, distribution, and sale of drugs in India.

Biological products, including vaccines and certain therapeutic products, must comply with applicable licensing, manufacturing, quality-control, and regulatory requirements.

The Act operates alongside the Drugs Rules, 1945, which prescribe detailed requirements concerning manufacturing licences, testing, standards, and inspections.

Distributed manufacturing facilities cannot assume that operating under one corporate organization automatically removes the need for facility-specific regulatory compliance.

2. Environment (Protection) Act, 1986

The Environment (Protection) Act, 1986 provides a comprehensive framework for controlling environmental risks arising from industrial and biotechnology activities.

The Rules for the Manufacture, Use, Import, Export and Storage of Hazardous Microorganisms/Genetically Engineered Organisms or Cells, 1989 establish requirements concerning genetically engineered organisms and specified hazardous microorganisms.

These rules are particularly important where distributed biomanufacturing facilities use genetically modified organisms or biological materials requiring regulatory oversight.

3. Biological Diversity Act, 2002

The Biological Diversity Act, 2002 regulates access to biological resources and associated knowledge, subject to its provisions and amendments.

It may become relevant when biomanufacturing projects use biological resources obtained from India for research, commercial utilization, or product development.

4. Factories Act, 1948 and occupational safety legislation

Manufacturing facilities must comply with applicable occupational health and workplace safety requirements.

The Factories Act, 1948 historically established important obligations concerning worker safety, hazardous processes, ventilation, machinery, and emergency arrangements. The Occupational Safety, Health and Working Conditions Code, 2020 is intended to consolidate several labour safety laws, subject to its commencement and implementation.

5. Biotechnology regulatory guidelines

The Department of Biotechnology (DBT), Review Committee on Genetic Manipulation (RCGM), and Genetic Engineering Appraisal Committee (GEAC) perform important regulatory and supervisory functions under the applicable biotechnology framework.

Their responsibilities include oversight of specified research, contained use, environmental release, and activities involving genetically engineered organisms.

Major components of distributed biomanufacturing governance

1. Regulatory authorization and licensing

Each manufacturing facility must identify the statutory permissions applicable to its products, manufacturing processes, and biological materials.

Regulatory compliance may include:

Manufacturing licences under applicable drug regulations.

Environmental permissions and pollution-control consents.

Biosafety approvals for regulated biological activities.

Factory and occupational safety compliance.

Quality-management and inspection requirements.

A distributed network should maintain a central regulatory compliance system while ensuring that every individual manufacturing location meets its own applicable obligations.

2. Quality control and product standardization

One major challenge in distributed manufacturing is maintaining consistent product quality across different facilities.

Biological products may be sensitive to temperature, contamination, production conditions, and variations in manufacturing processes.

The Drugs and Cosmetics Rules, 1945 and applicable Good Manufacturing Practices (GMP) requirements establish important standards for pharmaceutical manufacturing.

Every participating facility should maintain validated processes, quality-control documentation, batch records, equipment calibration, and product-testing arrangements.

Centralized quality oversight can help maintain consistency without eliminating the responsibilities of individual manufacturing facilities.

3. Biosafety and environmental governance

Distributed biomanufacturing facilities may handle genetically modified organisms, microbial cultures, biological waste, and potentially hazardous substances.

Therefore, appropriate containment measures, waste treatment systems, emergency response procedures, and environmental monitoring are essential.

Facilities must follow applicable biosafety requirements and ensure that biological materials are handled, transported, and disposed of lawfully.

Environmental governance should also address wastewater discharge, air emissions, chemical storage, and accidental biological releases.

4. Digital governance and data management

Distributed biomanufacturing relies on digital technologies to coordinate manufacturing activities across different facilities.

These systems may collect production data, quality-control results, equipment performance information, supply-chain records, and regulatory documentation.

Governance frameworks should address:

Data accuracy and traceability.

Cybersecurity and access controls.

Protection of confidential manufacturing information.

Electronic record maintenance.

Secure communication between facilities.

Reporting of technical failures and product-quality incidents.

The Digital Personal Data Protection Act, 2023 may apply where distributed manufacturing systems process digital personal data, subject to applicable commencement and implementation provisions.

5. Supply-chain and transportation governance

Biological products frequently require specialized storage and transportation conditions.

Vaccines, enzymes, cell-based products, and other temperature-sensitive materials may lose quality if storage requirements are not maintained.

A distributed manufacturing governance framework should establish clear responsibilities for packaging, transportation, temperature monitoring, product identification, and traceability.

Supply-chain agreements should also define liability where products are damaged, contaminated, delayed, or improperly stored.

6. Intellectual property and technology transfer

Distributed manufacturing partnerships frequently involve licensing production technologies to multiple regional facilities.

Disputes may arise concerning ownership of manufacturing processes, patent rights, confidential production methods, and access to proprietary biological technologies.

The Patents Act, 1970 and Indian Contract Act, 1872 provide important legal frameworks for protecting intellectual property and enforcing technology transfer agreements.

Licensing arrangements should specify permitted manufacturing activities, quality obligations, royalty payments, confidentiality, and restrictions on unauthorized technology use.

Institutional responsibilities and accountability

Distributed biomanufacturing requires coordination among several institutions.

The exact authority depends on the product, manufacturing process, location, and applicable statutory requirements.

Important judicial decisions

There are relatively few Indian judgments directly addressing distributed biomanufacturing. However, several judicial decisions establish principles that are highly relevant to its governance.

1. M.C. Mehta v. Union of India (1987) – Oleum Gas Leak Case

The Supreme Court developed the principle of absolute liability for enterprises engaged in hazardous or inherently dangerous activities.

The Court held that enterprises conducting such activities have a non-delegable duty to ensure that no harm results from their operations.

This principle is important for distributed biomanufacturing because companies operating multiple facilities cannot avoid responsibility merely by distributing production activities among different locations.

Legal significance: Each facility must maintain appropriate safety arrangements, containment systems, and emergency procedures. Corporate decentralization does not eliminate legal accountability.

2. Indian Council for Enviro-Legal Action v. Union of India (1996)

The Supreme Court emphasized the polluter pays principle and environmental restoration responsibilities.

The decision established that organizations responsible for environmental pollution may be required to bear the costs of restoring affected environments.

Legal significance: Distributed biomanufacturing companies must ensure proper disposal of biological and chemical waste. Environmental damage caused by one manufacturing unit may create significant legal and financial consequences.

3. Vellore Citizens' Welfare Forum v. Union of India (1996)

The Supreme Court recognized the precautionary principle and polluter pays principle as essential components of Indian environmental law.

The judgment emphasized that environmental protection should be preventive rather than merely corrective.

Legal significance: Distributed manufacturing facilities should conduct environmental risk assessments before introducing new production processes, particularly where genetically engineered organisms or hazardous biological materials are involved.

4. A.P. Pollution Control Board v. Prof. M.V. Nayudu (1999)

The Supreme Court examined environmental decision-making involving scientific uncertainty and technical expertise.

The judgment highlighted the importance of scientific knowledge and expert assessment in environmental regulatory decisions.

Legal significance: Distributed biomanufacturing requires technically informed regulatory supervision because different facilities may involve different biological risks, production methods, and environmental conditions.

5. Novartis AG v. Union of India (2013)

The Supreme Court examined the patentability of pharmaceutical inventions under Section 3(d) of the Patents Act, 1970.

The Court emphasized the statutory requirements for patent protection and rejected an approach that would permit evergreening without satisfying the applicable legal standard.

Legal significance: Distributed biomanufacturing partnerships must carefully distinguish between patentable innovations, existing technologies, and improvements to previously known products. Technology transfer agreements must respect Indian patentability requirements.

Major challenges in distributed biomanufacturing governance

Despite its economic and scientific advantages, distributed biomanufacturing creates several regulatory challenges.

Regulatory fragmentation: Different facilities may face different licensing and inspection requirements.

Quality inconsistency: Maintaining identical manufacturing standards across multiple locations can be difficult.

Biosafety risks: Decentralized production increases the importance of consistent containment and monitoring procedures.

Data security: Connected manufacturing systems may become vulnerable to unauthorized access and data manipulation.

Supply-chain complexity: Transportation and storage failures can affect product quality.

Accountability disputes: It may be difficult to determine responsibility when manufacturing, testing, packaging, and distribution involve different organizations.

Technology transfer conflicts: Disagreements may arise concerning patents, confidential information, and licensing arrangements.

Recommendations for strengthening governance frameworks

India should strengthen distributed biomanufacturing governance through coordinated regulatory supervision and standardized compliance systems.

Important measures include:

Establishing facility-specific regulatory compliance records.

Strengthening GMP inspections and independent quality audits.

Maintaining centralized product traceability systems.

Introducing consistent biosafety and environmental monitoring standards.

Establishing clear liability arrangements between manufacturing partners.

Improving cybersecurity and electronic record protection.

Strengthening cooperation between national and state regulatory authorities.

Conducting periodic emergency preparedness and risk assessments.

A risk-based regulatory approach can also help distinguish between low-risk biological manufacturing activities and operations involving higher-risk biological materials.

Conclusion

Distributed biomanufacturing governance frameworks are essential for ensuring the safe, reliable, and legally compliant production of biological products across geographically separated facilities. They integrate pharmaceutical regulation, biosafety, environmental protection, intellectual property rights, digital governance, and corporate accountability.

In India, the Drugs and Cosmetics Act, 1940, Environment (Protection) Act, 1986, Biological Diversity Act, 2002, and applicable biotechnology regulations provide important foundations for governing distributed manufacturing activities.

Judicial decisions such as M.C. Mehta v. Union of India, Vellore Citizens' Welfare Forum v. Union of India, and A.P. Pollution Control Board v. Prof. M.V. Nayudu establish principles of absolute liability, environmental precaution, and scientific accountability.

Ultimately, successful distributed biomanufacturing requires coordinated regulatory oversight, standardized quality controls, transparent institutional responsibilities, and effective biosafety management. These measures can strengthen India's biotechnology manufacturing capacity while protecting public health, environmental sustainability, and scientific integrity.